FDA challenges claims that biological products can treat serious diseases without demonstrating their safety and effectiveness through the agency’s approval process
Stem cell therapies and products derived from human placental tissue have attracted considerable attention for their potential medical applications. But promising technology and claims of therapeutic benefits are not substitutes for FDA approval.
On September 25, 2026, the FDA’s Center for Biologics Evaluation and Research (CBER) issued a warning letter to Beaute Bounty, a company located in Kuala Lumpur, Malaysia, for marketing unapproved stem cell and placenta-derived products.
According to FDA, the company offered products promoted for treating conditions ranging from chronic pain and diabetes to cardiovascular and neurological diseases, without the required FDA authorization.
What was the company selling?
FDA identified three products advertised through the company’s website:
Evgenis Totipotent Embryonic Stem Cells, promoted for conditions including chronic joint pain, spinal cord injuries, cardiovascular disease, diabetes, Parkinson’s disease, multiple sclerosis, and Alzheimer’s disease.
Laennec, described as a human placenta hydrolysate, with claims involving liver conditions, anemia, diabetes, hypertension, and other health problems.
Melsmon Placenta Japan, another placenta-derived product, promoted for cellular rejuvenation, tissue regeneration, improved circulation, and other physiological benefits.
These are significant medical claims, particularly for patients facing chronic or serious diseases for which effective treatments may be limited.
However, FDA determined that the products were being marketed as unapproved new drugs and unlicensed biological products.
The agency stated that the products lacked an approved Biologics License Application (BLA), which is generally required before biological products of this type can be lawfully marketed in the United States.
Why FDA approval matters
Biological products are often complex materials derived from living organisms or human tissues. Their safety and effectiveness cannot be assumed simply because they originate from the human body.
Depending on the product, important questions may include whether it is manufactured consistently, whether it contains contaminants, how it behaves after administration, and whether clinical evidence supports its advertised benefits.
FDA’s biologics licensing process evaluates whether a product meets applicable standards for safety, purity, and potency.
Without the required approval, consumers lack the assurance that FDA has evaluated the product under those standards for its advertised medical uses.
Importantly, the warning letter does not establish that every product caused harm or that every therapeutic claim is necessarily false. It establishes that the products were being marketed without the required authorization.
Not all human tissue products are regulated the same way
One of the central issues in the warning letter involves a regulatory concept called homologous use.
Under FDA regulations, certain human cells, tissues, and cellular or tissue-based products (HCT/Ps) may qualify for regulation solely under Section 361 of the Public Health Service Act when they meet specific criteria.
One requirement is that the tissue be intended to perform the same basic function in the recipient that it performed in the donor.
For example, the placenta performs important functions during pregnancy, including facilitating the transport of substances between maternal and fetal circulation.
Using placenta-derived products to treat diabetes, hypertension, or neurological disease does not represent that same basic function.
FDA concluded that Beaute Bounty’s products failed the homologous-use requirement and therefore could not qualify for regulation solely under Section 361.
Instead, the products were subject to additional drug and biological product requirements, including applicable premarket approval.
What consumers should understand
The availability of a stem cell or placenta-derived product on a commercial website does not mean that FDA has reviewed or approved it.
Consumers should be particularly cautious when products are advertised as treatments for numerous unrelated diseases or promise broad benefits such as cellular rejuvenation, tissue regeneration, or restoration of organ function.
Such claims may sound scientifically promising, but they require appropriate evidence.
Before considering a stem cell or other human tissue-derived treatment, patients should ask whether the specific product is FDA-approved for the proposed use, what clinical evidence supports the treatment, and what risks may be involved.
Consumers can also consult FDA’s information about unapproved regenerative medicine products and report suspected adverse reactions through the agency’s MedWatch safety reporting program.
FDA’s enforcement action
FDA directed Beaute Bounty to address the violations and provide a written response within 15 working days of receiving the warning letter.
The agency warned that failure to adequately resolve the violations could result in additional regulatory action, including seizure or injunction.
Although Beaute Bounty is located in Malaysia, FDA’s warning addresses the marketing and introduction of products into U.S. interstate commerce without the required authorization.
The bigger picture
Stem cell research and regenerative medicine continue to offer important possibilities for future medical treatments. But there is a substantial difference between a technology with scientific potential and a product that has demonstrated sufficient safety and effectiveness to obtain regulatory approval.
The Beaute Bounty warning letter illustrates why that distinction matters.
For consumers, the essential question is not whether a product contains stem cells or human tissue. It is whether the product has been appropriately evaluated and authorized for the medical treatment being advertised.
Links
Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes.
